Triumvira
Home - Triumvira Immunologics | Engineered T Cell Therapies
- Business Model
- B2B
- Website
- triumvira.com
- Last Round
- Extension RoundMar 2022
- Rounds
- 2
About
Clinical-stage biotech developing engineered T cell therapies using TAC technology for autologous and allogeneic cancer treatment.
Summary
Triumvira is a Biotech company based in Canada. Its most recent funding was an Extension Round round in Mar 2022. Investors include B Capital Group, Oceanpine Capital and Northpond Ventures.
Tech & App Stack
6 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company